Publications by authors named "Krista L McNicol"
Article Synopsis
- Tirapazamine, a hypoxic cytotoxin, causes central vascular dysfunction in various tumor models, leading to non-perfused areas within tumors shortly after treatment.
- Carbogen breathing can reduce the number of tumors responding to tirapazamine, but it doesn't completely fix the vascular dysfunction it causes.
- The mechanism of tirapazamine's effects may involve inhibition of nitric oxide synthase (NOS), and initial experiments suggest that using NOS inhibitors could enhance tumor necrosis in certain tumor models.
Background And Purpose: Tirapazamine is a hypoxic cytotoxin currently undergoing Phase II/III clinical evaluation in combination with radiation and chemotherapeutics for the treatment of non-hematological cancers. Tissue penetration studies using multicellular models have suggested that tirapazamine exposure may be limited to cells close to blood vessels. However, animal studies show tirapazamine enhances the anti-tumour activity of radiation and chemotherapy and clinical studies with tirapazamine, so far, are promising.
View Article and Find Full Text PDF